Biopharma Leaders Talk Radical Steps, Regulatory Reform, Open AI To Spur India R&D

Biopharma experts including Nobel Laureate Professor Jack Szostak share their views on emerging innovation ecosystems and how India can get it right as it seeks to shift gears in R&D. Panelists noted that VC investments can be a mixed bag, called for regulatory vision that ensures safety alongside accelerated pathways like the LPAD in the US and also ‘open” AI platforms.

L-R: Dr. Ajit Rangnekar, Dr. Harish Iyer, Dr. Yamuna Krishnan, Dr. Radha Rangarajan, Mr Satish Reddy, Professor Jack W. Szostak, Dr. Guru N. Reddy, Dr. Shridhar Narayanan, Dr. Ravindranathan, Dr. Murali Ramachandra, Dr. Srinivas Oruganti, Anju Ghangurde, Tejasvi Poorna Chandra and Dinesh Reddy Musukula. • Source: Dr Reddy's Laboratories

More from R&D

More from Scrip